Search This Blog

Wednesday, April 9, 2025

'ADHD meds taken by millions of people toxic for your heart'

 This little pill — taken by adults and children alike — might just be a prescription for heart disease.

Dr. Evan Levine is an experienced cardiologist in Scarsdale, New York, who also runs a very popular TikTok channel, where he gets real about everything from heart attacks and health care quacks to the truth about your favorite Starbucks drink.

Speaking to The Post, the veteran heart doctor tackled a drug that is commonly prescribed to help children perform better on tests and sports — a phenomenon he calls “borderline child abuse.”

Dr. Evan Levine tackles a drug that is often prescribed to help children perform better.tiktok/@drevanlevine

“There are two classes of stimulants for ADHD,” Levine said.

“One is the Ritalin-derived drugs called methylphenidates — Ritalin and Concerta are the most popular — and the other is the amphetamine class like Adderall and Vyvanse.”

Both types, he said, “increase the levels of norepinephrine in the blood, which can lead to slightly higher blood pressure and a mild increase in risk of arrhythmias.”

That might sound minor, but new research and common-sense questions have Levine sounding the alarm.

‘The FDA never did their job’

“In 2011, the Food and Drug Administration used a study to confirm the safety of these stimulant medications and they concluded — among young and middle-aged adults — [that there is] no increase in cardiovascular events,” Levine pointed out.

“But the study clearly states the average follow-up was only 1.3 years,” he added. “So, yeah, young healthy people have no risk at 1.3 years with elevated norepinephrine levels in their blood.”

Here comes the however.

“We know that very elevated levels of norepinephrine for years, like in people with adrenal tumors and heart failure, can adversely affect the heart — levels are much higher here,” Levine said.

“What if a child takes this for 20 years? The FDA never commented on this. Or an elderly patient takes this — or anyone at risk, people with congenital heart conditions like a bicuspid aortic valve, which 1.5% of the population has and are at risk for aortic aneurysms? The FDA never did their job.”

And now? The longer-term data is starting to back him up.

“In April 2024, they find that when you follow them up for eight years, young healthy people aged 20 to 40, they have a 57% higher risk than young healthy people not on these meds,” Levine said.

“It ends up that 1/500 of these patients were diagnosed with a cardiomyopathy.”

“Young, healthy people aged 20 ti 40, they have a 57% higher risk” of heart disease, Levine said of the new study.exxxplosion – stock.adobe.com

Millions of kids could be at risk

Levine, who also tackled the subject on TikTok, noted that the sheer volume of Americans taking these meds could be a ticking time bomb — recent data suggested 1 in 9 kids these days have been diagnosed with ADHD.

“The numbers of young adults on this since childhood can be significant,” he said.

But it’s not just kids: A recent study showed 1 in 17 adults have been diagnosed with ADHD, and some experts questioned whether or not all of these cases are legitimate.

Levine said people are taking it without an ADHD diagnosis, only to help them “focus better on exams or perform better in sports.”

Plus, he added, the drugs may have a greater risk for adults who may have hypertension or underlying heart disease.

“The numbers of young adults on this since childhood can be significant,” Levine said.Irina Schmidt – stock.adobe.com
‘Like a local drug dealer meets telemedicine’

Telehealth services have supercharged the trend, Levine warned — potentially making the drugs available to anyone with a credit card and Wi-Fi access.

“Who is vetting these services? ‘Hi, my name is Evan and I cannot concentrate and need some Adderall. Thank you,’” he said.

According to Levine, what’s lacking is comprehensive mental health care and careful consideration of non-stimulant options.

“With better behavioral health, available psychiatric evaluation and alternatives like non-stimulants, of course the amount of prescriptions for these drugs will diminish,” he said.

A loophole in plain sight

Levine pointed out that these meds are taken seriously — even banned — in certain fields unless a formal diagnosis is proven.

“In Olympic sports, you need to apply for an exemption and demonstrate you have ADHD. Otherwise, you are disqualified,” he said.

“One can only guess there are some that claim a diagnosis to improve their ability and concentration in a sport.”

So, what now? For Levine, the message is simple: ADHD should absolutely be treated — but with more caution, more oversight and less blind trust in pills.

https://nypost.com/2025/04/09/health/cardiologist-warns-commonly-prescribed-drug-is-toxic-for-heart/

Social Security abandons phone service cuts after backlash

The U.S. Social Security Administration abandoned plans to end phone services for retirees that would have started on Monday, following a growing outcry from advocates who warned that the changes could cause chaos and further strain the agency.

The agency, which pays out $1.4 trillion in benefits to 73 million Americans annually, said on Wednesday it would "allow all claim types to be completed over the telephone," from April 14, the date that the phone option was due to be cut.

"Telephone remains a viable option to the public," the SSA said in an emailed statement to Reuters.

It gave no reason for the abrupt reversal. Just two weeks ago, the SSA said that starting Monday all retirees, widows and children would have to visit a field office if they were unable to verify their identity and apply for benefits online.

The SSA had estimated that canceling the phone option would prompt 75,000 to 85,000 more people per week to seek the help of a person at field offices, leading to roughly 4 million additional office visits annually.

The SSA, which had cited concerns about fraud when it initially announced the plan to curtail phone services, said on Wednesday it would conduct a fraud check on all benefit claims made over the telephone and flag those deemed risky.

"Individuals that are flagged would be required to perform in-person ID proofing for the claim to be further processed," the SSA said. "Individuals who are not flagged will be able to complete their claim without any in-person requirements."

https://www.yahoo.com/news/social-security-abandons-phone-cuts-200407444.html

Russian Duma Ratifies 20-Year Defense, Energy Pact With Iran

 Via The Cradle

Russia's State Duma ratified the comprehensive strategic partnership agreement between Russia and Iran in its plenary session on 8 April, Sputnik reported.

"The agreement lays a solid foundation for expanding the comprehensive Russian–Iranian partnership in all areas, including defense, counterterrorism, energy, finance, transportation, industry, science, and technology," the Russian news outlet stated. The treaty was concluded for 20 years, with the possibility of a subsequent five-year extension.

Russian State Duma, handout via Reuters

The agreement was signed by Russian President Vladimir Putin and his Iranian counterpart, Masoud Pezeshkian, before being voted on in the Duma. The Russian president stated, "The partnership agreement between Russia and Iran aims to create conditions for stable and sustainable development" for both countries and the broader region.

Putin added that "Russia and Iran are pursuing independent paths on the global stage and are resisting external pressure and the application of illegitimate sanctions."

Russia and Iran have been targeted by harsh US economic sanctions in recent years. Regarding the agreement, Iranian Foreign Minister Abbas Araghchi stated, "Iran and Russia, as two large and powerful countries, play a prominent role in shaping the new world order."

"Iran, with its strategic location at the center of energy geography and international trade, and Russia, as a country with endless resources, advanced industry, and extensive influence, have enormous potential for cooperation," Araghchi added.

The comprehensive strategic partnership agreement between Russia and Iran replaces the current security agreement signed by both countries in 2001.

The Duma ratified the treaty as trilateral consultations were underway in Moscow between Russia, China, and Iran on the Iranian nuclear program.

The consultations "will discuss various aspects related to the nuclear issue, the Joint Comprehensive Plan of Action and UN Security Council Resolution 2231," Iranian Foreign Ministry spokesman Esmail Baghai stated Tuesday during his weekly news briefing.

The three countries previously held consultations on Iran's nuclear program on March 14. The US and Israel are demanding that Iran enter negotiations over its nuclear program. They claim Iran is seeking a nuclear weapon. Iran has stated that its program is for civilian use and that nuclear weapons are un-Islamic.

On March 7, US President Donald Trump sent a letter to the leadership in Tehran asking for direct negotiations.

Trump's letter issued a clear threat – negotiate or risk a bombing campaign against the Iranian nuclear program. The US president later reiterated this threat, saying in late March that "If they don't make a deal, there will be bombing."

Trump told reporters on Monday, following his meeting with Israeli Prime Minister Benjamin Netanyahu, that Washington will be "having direct talks with Iran, and they've started." However, Iranian Foreign Minister Abbas Araghchi said that Tehran will only engage in "indirect" nuclear negotiations with the US via Oman.

https://www.zerohedge.com/geopolitical/russian-duma-ratifies-20-year-defense-energy-pact-iran

Goldman Calls "US Recession" At 12:57pm; 73 Minutes Later Rescinds Recession Call

 Yesterday morning, when we were flooded with a barrage of apocalyptically bearish "research" by a generation of Wall Street sellside bankers who seemingly never lived through Trump's first trade war which which, as we explained previously, followed the following very simple algorithm...

... we predicted that it would be ever so "slightly awkward when all the banks who made a recession their base case this week, make an unrecession their base case in 1 month."

One day later, we were right.... but not even we had an idea just how right we would be. Because in what was perhaps the pinnacle of Wall Street flipflopping, arguably the most important US bank made announced just before 1pm that it had made a recession its base case... and 73 minutes later rescinded the call!

No really: here is the sequence of events. At12:57pm Goldman chief economist Jan Hatzius publishes a report titled "Moving to a Recession Baseline." 

Great... only 20 minutes later Trump steamrolled all over Wall Street's laughable "scenarios" (as if they really don't know how Trump negotiates yet), and blew up every single bearish scenario. And sure enough, at 2:10pm, or about 73 minutes after Hatzius emailed his first note, the Goldman chief economist published a note titled "President Trump Announces 90 Day Pause; Reverting to Our Previous Non-Recession Baseline."

Just like that the first recession call is over.

And now we wait as the rest of Wall Street's penguin crew falls in line and does the exact same thing.

https://www.zerohedge.com/markets/goldman-calls-us-recession-1257pm-73-minutes-later-rescinds-recession-call

Bessent singles out Beijing amid tariff pause: ‘Problem for the rest of the world’

 Treasury Secretary Scott Bessent said that China is at odds with the rest of the world as the Trump administration alleviated tariffs for everyone but Beijing on Wednesday. 

President Donald Trump announced Wednesday that he would reduce recently imposed reciprocal tariffs on several countries, while also revealing an immediate increase in tariffs on Chinese goods to 125%.

"China is the most imbalanced economy in the history of the modern world," Bessent told reporters Wednesday. "They are the biggest source of the U.S. trade problems, and indeed they are the problem for the rest of the world." 

On Wednesday, duties of 104% took effect against Chinese goods entering the U.S. — prompting China to respond by upping its tariffs on U.S. goods from 34% to 84%.

"I'm not calling it a trade war, but I think that China has escalated, and President Trump responded very courageously to that, and we are going to work on a solution with our trading partner," Bessent said. 

By contrast, Bessent said that more than 75 countries have contacted the Trump administration to work on hashing out a trade solution, and he expects more will do so after Wednesday. 

Commerce Secretary Howard Lutnick voiced similar sentiments, and said that China deviated from other countries in refusing to come to the negotiating table with the U.S. to broker a new trade deal. 

placeholder

"The world is ready to work with President Trump to fix global trade, and China has chosen the opposite direction," Lutnick said in a post on X, formerly Twitter, on Wednesday. 

Trump disclosed historic tariffs in a ceremony at the White House’s Rose Garden for a "Make America Wealthy Again" event on April 2, asserting these new duties would generate new jobs for U.S. workers.

The tariff plan established a baseline tax of 10% on all imports to the U.S., along with customized tariffs for countries that place higher tariffs on American goods. The baseline tariffs of 10% took effect Saturday, while the others took effect Wednesday at midnight. 

Trump announced in a post on Truth Social Wednesday that reciprocal tariffs announced last week would remain paused for 90 days, during which period the countries would only face the baseline 10% tariff. 

"At some point, hopefully in the near future, China will realize that the days of ripping off the U.S.A., and other Countries, is no longer sustainable or acceptable," Trump posted on his Truth Social media platform on Wednesday. 

https://www.foxbusiness.com/politics/bessent-singles-out-beijing-amid-tariff-pause

Tivic Health expands license with Statera

 Tivic Health Systems , Inc. (NASDAQ:TIVC), a medical device company specializing in bioelectronic medicine with a market capitalization of $2 million, announced on Monday that it has exercised an exclusive option to extend its licensing agreement with Statera Biopharma, Inc. for the development of a treatment for Neutropenia, a condition characterized by an abnormally low count of neutrophils, a type of white blood cell. The company’s stock, which has seen significant volatility recently, is currently trading at $4.82, marking an 11.3% gain over the past week. According to InvestingPro analysis, the stock appears to be trading below its Fair Value.

Under the terms of the original agreement dated February 11, 2025, Tivic Health paid Statera a license fee of $1.5 million, which included both cash and stock considerations, for the rights to Entolimod, a proprietary Toll-like Receptor 5 (TLR5) agonist program. The new option grants Tivic Health exclusive worldwide rights to further indications of this program, specifically for Neutropenia. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 9.7, indicating robust ability to meet short-term obligations.

To facilitate this expansion, Tivic Health has issued additional equity securities to Statera and Avenue Venture Opportunities Fund, L.P., consisting of 55,704 shares of common stock and 131.1267 shares of Series A Preferred Stock. This issuance is part of an advanced milestone payment arrangement related to the development progress of the treatment.

The transaction is exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) of the Act and/or Regulation D promulgated thereunder, with the securities being issued only to accredited investors.

https://www.investing.com/news/sec-filings/tivic-health-expands-license-with-statera-biopharma-93CH-3966651

Phio Pharma to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort



Phio Pharmaceuticals (NASDAQ: PHIO) announced positive safety results for the third cohort in its Phase 1b clinical trial of PH-762, their lead INTASYL® siRNA compound for skin cancer treatment. The Safety Monitoring Committee recommended advancing to the fourth dose escalation cohort following successful results in three cutaneous squamous cell carcinoma patients, who showed no serious adverse events or dose-limiting toxicities.

The multi-center trial (NCT 06014086) evaluates PH-762's safety and tolerability in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Prior results from cohorts 1 and 2, comprising seven patients, showed promising outcomes. In the second cohort, two patients achieved complete response (100% tumor clearance) and one patient showed partial response (90% clearance) by Day 36. All three patients in cohort 1 and one patient in cohort 2 maintained stable disease.